Download PDF
Thromb Haemost 2002; 88(06): 888-889
DOI: 10.1055/s-0037-1613328
Commentary
Schattauer GmbH

Platelet Glycoprotein IIb/IIIa Inhibitors and Thrombocytopenia: Possible Link between Platelet Activation, Autoimmunity and Thrombosis

Charles S. Abrams
1   Hematology-Oncology Division, University of Pennsylvania, Philadelphia, USA
,
Douglas B. Cines
2   Dept. of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, USA
› Author Affiliations
Further Information

Publication History

Received 16 August 2002

Accepted 20 August 2002

Publication Date:
09 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Lefkovits J, Plow EF, Topol EJ. Mechanisms of disease: Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-59.
    CrossrefPubMedGoogle Scholar
  • 2 Nurden AT, Poujol C, Durrieu-Jais C, Nurden P. Platelet glycoprotein IIb/IIIa inhibitors: basic and clinical aspects. Arterioscler Thromb Vasc Biol 1999; 19: 2835-40.
    CrossrefPubMedGoogle Scholar
  • 3 Bennett JS, Mousa S. Platelet function inhibitors in the Year 2000. Thromb Haemost 2001; 85: 395-400.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Berkowitz SD, Sane DC, Sigmon KN, Shavender JH, Harrington RA, Tcheng JE, Topol EJ, Califf RM. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol 1998; 32: 311-9.
    CrossrefPubMedGoogle Scholar
  • 5 The EPIC Investigation. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
    CrossrefPubMedGoogle Scholar
  • 6 Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349: 1429-35.
    CrossrefPubMedGoogle Scholar
  • 7 Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997; 336: 1689-96.
    CrossrefPubMedGoogle Scholar
  • 8 Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352: 87-92.
    CrossrefPubMedGoogle Scholar
  • 9 Billheimer JT, Dicker IB, Wynn R, Bradley JD, Cromley DA, Godonis HE, Grimminger LC, He B, Kieras CJ, Pedicord DL, Spitz SM, Thomas BE, Zolotarjova NI, Gorko MA, Hollis GF, Daly RN, Stern AM, Seiffert D. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood 2002; 99: 3540-6.
    CrossrefPubMedGoogle Scholar
  • 10 Tcheng JE, Kereiakes DJ, Lincoff AM, George BS, Kleiman NS, Sane DC, Cines DB, Jordan RE, Mascelli MA, Langrall MA, Damaraju L, Schantz A, Effron MB, Braden GA. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 2001; 104: 870-5.
    CrossrefPubMedGoogle Scholar
  • 11 Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) study investigators. N Engl J Med 1998; 338: 1488-97.
    CrossrefPubMedGoogle Scholar
  • 12 Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT trial investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med 1998; 339: 436-43.
    CrossrefPubMedGoogle Scholar
  • 13 Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in myocardial mnfarction. Circulation 1998; 97: 340-9.
    CrossrefPubMedGoogle Scholar
  • 14 Giugliano RP, McCabe CH, Sequeira RF, Frey MJ, Henry TD, Piana RN, Tamby JF, Jensen BK, Nicolas SB, Jennings LK, Wise RJ, Braunwald E. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials. Am Heart J 2000; 140: 81-93.
    CrossrefPubMedGoogle Scholar
  • 15 Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet 2000; 355: 337-45.
    CrossrefPubMedGoogle Scholar
  • 16 Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002; 99: 2054-9.
    CrossrefPubMedGoogle Scholar
  • 17 Bednar B, Cook JJ, Holahan MA, Cunningham ME, Jumes PA, Bednar RA, Hartman GD, Gould RJ. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood 1999; 94: 587-99.
    PubMedGoogle Scholar
  • 18 Hantgan RR, Rocco M, Nagaswami C, Weisel JW. Binding of a fibrinogen mimetic stabilizes integrin dIIIbβ3’s open conformation. Protein Sci 2001; 10: 1614-26.
    CrossrefPubMedGoogle Scholar
  • 19 Gawaz M, Ruf A, Neuman F-J, Pogatsa-Murray G, Dickfield T, Zohlnhofer D, Schomig A. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Thromb Haemost 1998; 80: 994-1001.
    Article in Thieme ConnectPubMedGoogle Scholar